tirzepatide or retatrutide how is different from Retatrutide vs. Tirzepatide: Dual vs. Triple Action, Doses, Benefits, Side Retatrutide vs Tirzepatide: Which Research

Tamer Coskun is the principal scientist who led the discovery, preclinical development, and early clinical proof-of-concept studies for GLP3

[DOI] [PubMed] [Google Scholar] 5.Nakagami T., DECODA Study Group Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin

Its a temporary program

Conclusion The emergence of GLP-1 receptor agonists as potential agents for cancer risk reduction represents a paradigm shift in our understanding of the relationship between metabolic health and oncology

While the prescribing information for GLP-1 medications does not specifically list Crohn's disease as a contraindication, the Summary of Product Characteristics (SmPC) for these medicines does advise caution in patients with gastrointestinal disease and states they are not recommended in severe gastrointestinal disease